ReviewFrontiers in medicine2026
Multiparametric MRI and artificial intelligence for non-invasive HER2 assessment in breast cancer: a comprehensive review.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the utility of multiparametric MRI (mpMRI) combined with radiomics and artificial intelligence (AI) for non-invasive assessment of human epidermal growth factor receptor 2 (HER2) status in breast cancer. Methods: Following the PRISMA 2020 guidelines, we searched PubMed, Web of Science, and Embase for studies published between January 2015 and December 2025 (last search: 27 June 2026). After duplicate removal using Zotero, two reviewers independently screened the records. Thirty-four studies were included and assessed using PROBAST, with the 16 radiomics studies additionally evaluated using the RQS. We qualitatively synthesized evidence on conventional MRI, diffusion imaging (DWI/ADC, IVIM, DKI, and DSI), DCE-MRI, metabolic MRI, and radiomics/AI approaches without performing a meta-analysis. Results: mpMRI sequences provide complementary insights into HER2 status. Advanced diffusion techniques (DKI: *p* = 0.003; DSI: AUC range, 0.700-0.721) and DCE-MRI radiomics provide predictive value by capturing microstructural and dynamic tumor characteristics. Multiparametric radiomics incorporating peritumoral features achieved AUCs of 0.84-0.923 for three-level HER2 classification, while radiomics and deep learning distinguished HER2-low from HER2-zero tumors with AUCs up to 0.892. Machine learning and deep learning models demonstrated moderate cross-center generalizability (external AUC, 0.66-0.84). However, variability in reference standards, retrospective study designs, and limited external validation remain major limitations. Conclusion: mpMRI combined with radiomics and AI demonstrates promising value for HER2 assessment, with internal testing often AUCs exceeding 0.90 but less consistent on external validation. It complements rather than replaces biopsy by capturing intratumoral heterogeneity and supporting treatment decisions. Future priorities include prospective multicenter validation, methodological standardization, and radiopathogenomic integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.